DiaMedica Therapeutics DMAC 深 沪
已收盘 08-14 16:00:00 美东时间
6.68
-0.070
-1.04%
华盛通- 最 高6.785
- 今 开6.74
- 成交量 16.52万股
- 最 低 6.55
- 昨 收 6.75
- 总市值 3.60亿
- 52周最高 10.4195
- 市盈率 静 --
- 换手率 0.31%
- 52周最低 5.14
- 委 比 42.35%
- 总股本 5388.33万
- 历史最高 10.88
- 量 比 1.14
- 振 幅 3.48%
- 历史最低 1.12
- 每 手 1
- 风险率 0.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration
Diamedica Therapeutics ( ($DMAC) ) has provided an update. DiaMedica Therapeuti...
08-11 23:11
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $12 price target.
08-11 23:02
DiaMedica Therapeutics Doses First Patients In Its Phase 2 Trial Of DM199 For The Treatment Of Fetal Growth Restriction
First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatment DM199 is intended to improve maternal uterine artery blood flow to the placenta without crossing into fetal circulation Fetal Growth Restriction...
06-23 20:34
DiaMedica Therapeutics Announces 75% Enrollment In Its Phase 2/3 ReMEDy2 trial of DM199 In Patients With Acute Ischemic Stroke
ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpasses 75% of Enrollment Required to Trigger Pre-Specified Interim AnalysisInterim Analysis by Independent DSMB Expected to Determine if a Sample Size Re-Estimation (Ranging
05-20 20:38
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
DiaMedica Therapeutics Highlights Clinical Gains Amid Trial Risks
Diamedica Therapeutics (($DMAC)) has held its Q4 earnings call. Read on for the...
04-05 08:13
Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
DiaMedica Therapeutics Gets No Objection Letter From Health Canada For Its Clinical Study Application Of DM199 In Phase 2 Trial In Participants With Early-Onset Preeclampsia
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced
03-05 20:38
